Easyhaler®: an overview of an inhaler device for day-to-day use in patients with asthma and chronic obstructive pulmonary disease

Article Page

Abstract

Inhalation therapy is likely to continue to dominate asthma and chronic obstructive pulmonary disease (COPD) treatment. The pressurised metered-dose inhaler (pMDI) accounts for most of the global inhaler market, but this kind of device is difficult to use properly. Dry powder inhalers (DPIs) have several advantages over pMDIs: they are breath-activated, easy and convenient to use, and environmentally friendly. The Easyhaler® (Orion; Finland) is a multidose reservoir-type DPI developed to efficiently deliver a wide range of medications, including fixed-dose combinations of bronchodilators and corticosteroids. Easyhaler shares a similar shape with the pMDI, and its performance is unaffected by moisture, dropping, vibration, and freezing/thawing. For these reasons, Easyhaler may be considered one of the most convenient inhalers for daily use in patients with asthma or COPD.

Keywords: asthma, chronic obstructive pulmonary disease, DPI performance, dry powder inhalers, Easyhaler®.

Citation: Lavorini F. Easyhaler®: an overview of an inhaler device for day-to-day use in patients with asthma and chronic obstructive pulmonary disease. Drugs in Context 2019; 8: 212596. DOI: 10.7573/dic.212596

Contributions: The author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, takes responsibility for the integrity of the work as a whole, and has given their approval for this version to be published.

Disclosure and potential conflicts of interest: In the last 3 years, Federico Lavorini has received grants for research, as well as fees for lectures and advisory boards, from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini International, Novartis, Orion Pharma, Teva, and Trudell. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at https://www.drugsincontext.com/wp-content/uploads/2019/05/dic.212596-COI.pdf

Acknowledgements: Editorial assistance was provided by Content Ed Net, with the helpful support of David Figgitt, PhD. Easyhaler, Turbuhaler and Nebuhaler are registered trademarks. The trademark symbol has been used on first occasion in the article but omitted after that for easier reading.

Funding declaration: Editorial assistance was supported by The Menarini Group.

Copyright: Copyright © 2019 Lavorini F. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Lavorini F. https://doi.org/10.7573/dic.212596. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/easyhaler-an-overview-of-an-inhaler-device-for-day-to-day-use-in-patients-with-asthma-and-chronic-obstructive-pulmonary-disease

Correspondence: Federico Lavorini, MD, PhD, Department of Experimental and Clinical Medicine, Careggi University Hospital, Largo Brambilla 3 – 50134 Florence, Italy. federico.lavorini@unifi.it

Provenance: submitted; externally peer reviewed.

Submitted: 18 April 2019; Peer review comments to author: 2 May 2019; Revised manuscript received: 15 May 2019; Accepted: 16 May 2019; Publication date: 5 June 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF